Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Compounds, called liamocins from Aureobasidium pullulans, having the general structure in Formula 1 are disclosed. ##STR00001##
where R.sub.1 is either COCH.sub.3 or H; and R.sub.2 is between two to ten O-linked 3,5-dihydroxydecanoate; and R.sub.3 can be a polyol (e.g., L- or D-glycerol, L- or D-threitol, L- or D-erythritol, L- or D-arabitol, L- or D-xylitol, L- or D-lyxitol, L- or D-ribitol, L- or D-allitol, L- or D-altritol, L- or D-mannitol, L- or D-iditol, L- or D-gulitol, L- or D-glucitol (also called sorbitol), L- or D-galactitol (also called dulcitol), and L- or D-talitol), 2-amino-D-mannitol, 2N-acetylamino-D-mannitol, L-rhamnitol, or D-fucitol; except when R.sub.3 is D-mannitol, R.sub.2 is not 2 nor 3 O-linked 3,5-dihydroxydecanoate chains. These liamocins described above in addition to D-mannitol liamocin A1, D-mannitol liamocin A2, D-mannitol liamocin B1, and D-mannitol liamocin B2, alone or in combination with each other, can be used to kill certain bacteria and to treat certain bacterial infections.

Compounds, called liamocins from Aureobasidium pullulans, having the general structure in Formula 1 are disclosed. ##STR00001##
where R.sub.1 is either COCH.sub.3 or H; and R.sub.2 is between two to ten O-linked 3,5-dihydroxydecanoate; and R.sub.3 can be a polyol (e.g., L- or D-glycerol, L- or D-threitol, L- or D-erythritol, L- or D-arabitol, L- or D-xylitol, L- or D-lyxitol, L- or D-ribitol, L- or D-allitol, L- or D-altritol, L- or D-mannitol, L- or D-iditol, L- or D-gulitol, L- or D-glucitol (also called sorbitol), L- or D-galactitol (also called dulcitol), and L- or D-talitol), 2-amino-D-mannitol, 2N-acetylamino-D-mannitol, L-rhamnitol, or D-fucitol; except when R.sub.3 is D-mannitol, R.sub.2 is not 2 nor 3 O-linked 3,5-dihydroxydecanoate chains. These liamocins described above in addition to D-mannitol liamocin A1, D-mannitol liamocin A2, D-mannitol liamocin B1, and D-mannitol liamocin B2, alone or in combination with each other, can be used to kill certain bacteria and to treat certain bacterial infections.

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

The present invention addresses the problem of providing a novel compound which readily dissolves in liquid epoxy resins and which can be a hardener for epoxy resins to give cured objects excellent in terms of heat resistance and chemical resistance. Provided as a means for solving the problem is a polyacyloxymethyl-4,4-acyloxybiphenyl compound represented by formula (1).

The present invention addresses the problem of providing a novel compound which readily dissolves in liquid epoxy resins and which can be a hardener for epoxy resins to give cured objects excellent in terms of heat resistance and chemical resistance. Provided as a means for solving the problem is a polyacyloxymethyl-4,4-acyloxybiphenyl compound represented by formula (1).

A liquid crystal composition without requiring an alignment film or alignment treatment on a substrate. The problem is solved by a low molecular weight polar compound capable of homogeneously aligning a liquid crystal medium relative to the substrate, for example, a low molecular weight polar compound represented by formula (1):

M-P(1)

In formula (1), M is a nonpolar group having 1 or more carbons, and P is a polar group.

Provided are methods for the isolation of phorbol from seed sources and the use of the phorbol for the generation of tigliane tiglate and derivatives thereof.